Core Viewpoint - Helix BioPharma Corp. has decided not to proceed with the previously announced equity draw-down subscription facility with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited due to a misalignment with its capital strategy and long-term shareholder value objectives [1][2]. Group 1: Financing Decision - The company entered into a non-binding term sheet with GEM on October 15, 2024, and received shareholder approval for the financing arrangement on March 26, 2025 [2]. - After evaluating market conditions and corporate objectives, Helix concluded that the GEM facility no longer aligns with its capital strategy [2]. - The letter of intent with GEM expired, and the company has chosen not to execute binding agreements or pursue financing with them [2]. Group 2: Future Financing Plans - Helix is actively engaging in discussions with financial partners to explore alternative financing structures that better align with its strategic direction [3]. - The company remains committed to securing the necessary capital to advance its clinical programs and achieve corporate objectives [3]. Group 3: Company Overview - Helix BioPharma is focused on developing innovative solutions for hard-to-treat cancers, with its pipeline led by Tumor Defense Breaker™ L-DOS47, which targets CEACAM6-expressing tumors [4]. - L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and is part of a broader strategy that includes next-generation bi-specific antibody-drug conjugates [4]. - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug [4].